ChemGenex completes SPP
Tuesday, 14 October, 2008
ChemGenex Pharmaceuticals [ASX: CXS] has completed its share placement program, raising over $13 million to fund the late-stage development of its omacetaxine candidate for chronic myeloid leukaemia.
15.3 million shares were placed during the program, trading at 85 cents each. During the period of the program, CXS shares traded at a high of 83 cents and a low of 72.5 cents.
All shares on offer were purchased. ChemGenex representatives said they were pleased the placement went so well considering the unstable global financial climate.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
